Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes

Diabetes

Volumn 46, Issue 2, 1997, Pages 287-291

  Heesom, Angela E ^a   Hibberd, Martin L ^a   Millward, Ann ^a   Demaine, Andrew G ^a  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; DINUCLEOTIDE; DNA;

ADOLESCENT; ADULT; ARTICLE; CAUCASIAN; CHILD; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; GENE FREQUENCY; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0030903087     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.2.287     Document Type: Article

References (37)

1. Andersen AR, Christiansen JS, Andersen JK, Kleiner S, Deckert T: Diabetic nephropathy in type I (insulin dependent) diabetes: an epidemiological study. Diabetologia 25:496-501, 1983
2. Laffel LMB, Krolewski AS: Epidemiology and clinical impact of diabetic late complications in IDDM. In Prevention and Treatment of Diabetic Late Complications. Mogensen CE, Standl E, Eds., Berlin, Walter de Gruyter, 1989, p. 13-27
3. The Diabetes Control and Complications Trial (DCCT) Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
4. Raskin P: Risk factors for the development of diabetic complications. J Diabetes Complications 8:195-200, 1994
5. Chowdhury TA, Kumar S, Barnett AH, Bain SC: Nephropathy in type I diabetes: the role of genetic factors. Diabet Med 2:1059-1067, 1995
6. Robinson WG, Kador PF, Kinoshita JH: Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor Science 221:1177-1179, 1983
7. Nishimura C, Lou MF, Kinoshita JH: Depletion of myo-inositol and amino acids in galactosemic neuropathy. J Neurochem 49:290-295, 1987
8. Cohen MP: Aldose reductase, glomerular metabolism, and diabetic nephropathy. Metabolism 3 (Suppl. 1):55-59, 1986
9. Boel E, Selmer J, Flodgaard HJ, Jensen T: Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise? J Diabetes Complications 9:104-129, 1995
10. van-Gerven JM, Tjon-A-Tsien AM: The efficacy of aldose reductase inhibitors in the management of diabetic complications: comparison with intensive insulin treatment and pancreatic transplantation. Drugs Aging 6:9-28, 1995
11. Dvornik D: Hyperglycaemia in the pathogenesis of diabetic complications. In Aldose Reductase Inhibition: An Approach to the Prevention of Diabetic Complications. Porte D, Ed. New York, McGraw-Hill, 1987, p. 7-151
12. Baynes JW: Role of oxidative stress in the development of complications of diabetes. Diabetes 40:405-412, 1991
13. Corbett JA, Tilton RG, Change K, Hassan KS, Ido Y, Wang JI, Sweetland MA, Lancaster JR, Williamson JR, McDaniel ML: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556, 1992
14. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, Van den Enden M, Kilo C, Tilton RG: Hyperglycaemic pseudohypoxia and diabetic complications. Diabetes 42:801-813, 1993
15. Cameron NE, Cotter MA: The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 10:189-224, 1994
16. Bohren KM, Bullock B, Wermuth B, Gabbay KH: The aldo-keto reductase superfamily: the cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J Biol Chem 264:9547-9551, 1989
17. Chung S, LaMendola J: Cloning and sequence determination of human placental aldose reductase gene. J Biol Chem 264:14,775-14,777, 1989
18. Nishimura C, Matsuura Y, Kokai Y, Akera T, Carper D, Morjana D, Lyons C, Flynn TG: Cloning and expression of human aldose reductase. J Biol Chem 265:9788-9792, 1990
19. Graham A, Brown L, Hedge PJ, Gammack AJ, Markham AF: Structure of the human aldose reductase gene. J Biol Chem 266:6872-6877, 1991
20. Graham A, Heath P, Morten JEN, Markham AF: The human aldose reductase gene maps to chromosome 7q35. Human Genet 86:509-514, 1991
21. Bateman JB, Kojis T, Heinzmann C, Klisak I, Diep A, Carper D, Nishimura C, Mohandas T, Sparkes RS: Mapping of aldose reductase gene sequences to human chromosomes 1, 3, 7, 9, 11 and 13. Genomics 17:560-565, 1993
22. Hibberd ML, Millward BA, Wong FS, Demaine AG: T-cell receptor constant β-chain polymorphisms and susceptibility to type I diabetes. Diabet Med 9:929-933, 1992
23. Patel A, Ratanachaiyavong S, Millward BA, Demaine AG: Polymorphisms of the aldose reductase locus (ALR2) and susceptibility to diabetic microvascular complications. Adv Exp Mol Biol 328:325-332, 1993
24. Patel A, Hibberd ML, Millward BA, Demaine AG: Chromosome 7q35 and susceptibility to diabetic microvascular complications. J Diabetes Complications 10:62-67, 1996
25. Ko BC-B, Lam KS-L, Wat NM-S, Chung SS-M: An (A-C)n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 44:727-732, 1995
26. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1044, 1979
27. Tiwari JL, Terasaki PI: The data and statistical analysis. In: HLA and Disease Associations. Tiwari JL, Terasaki PI, Eds. New York, Springer-Verlag, 1985, p. 18-27
28. Jennings PE, Nightingale S, Le Guen C, Lawson N, Williamson JR, Hoffman P, Barnett AH: Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy. Diabet Med 7:63-68, 1990
29. Pedersen MM, Christiansen JS, Mogensen CE: Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 months of aldose reductase inhibition. Diabetes 40:527-531, 1991
30. Passariello N, Sepe J, Marrazzo G, De Cicco A, Peluso A, Pisano MC, Sgam-bato S, Tesauro P, D'Onofrio F: Effect of aldose reductase inhibitor (toIrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care 16:789-795, 1993
31. Beyer-Mears A, Murray FT, Del Val M, Cruz E, Sciadini M: Reversal of proteinuria by sorbinil, an aldose reductase inhibitor in spontaneously diabetic (BB) rats. Pharmacology 36:112-120, 1988
32. Frank RN: Aldose reductase controversy. Diabetes 43:169-172, 1994
33. Hamada Y, Kitoh R, Raskin P: Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients. Diabetes 40:1233-1240, 1991
34. Hamada Y, Kitoh R, Raskin P: Association of erythrocyte aldose reductase activity with diabetic complications in type I diabetes mellitus. Diabet Med 10:33-38, 1993
35. Nishimura C, Saito T, Ito T, Omori Y, Tanimoto T: High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia 37:328-330, 1994
36. Wang K, Bohren KM, Gabbay KH: Characterisation of the human aldose reductase gene promoter. J Biol Chem 268:16052-16058, 1993
37. Ferraris JD, Williams CK, Martin BM, Burg MB, Garcia-Perez, A: Cloning, genomic organization, and osmotic response of the aldose reductase gene. Proc Natl Acad Sci USA 91:10742-10746, 1994